A Phase II study of Gefitinib as First-Line Treatment for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2015
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Apr 2011 Status changed from recruiting to active, no longer recruiting according to UMIN.
- 09 Apr 2009 New trial record.